Non-Hereditary Solid Tumor NGS Panel (Liquid Biopsy) Test


GCG-Oncomine Pan-cancer (LBx) Analysis Service


A non-hereditary solid cancer NGS panel test (liquid biopsy) that examines DNA released from tumor cells (circulating tumor DNA) found in the peripheral blood of patients with malignant solid carcinoma.

It is a laboratory developed test (LDT) of GC Genome utilizing the Oncomine Pan cancer Cell-free Assay(RUO) from Thermofisher


What is Liquid Biopsy and Why do we Need it?


In general, tissue biopsy (an invasive procedure to remove sample tissue) is performed for diagnosis of cancer. However, this is not always possible depending on the location of the tumor and the condition of the patients.


Also, the information from tissue biopsy is specific to the biological characteristic of the collected tumor tissue. So, in some cases this information cannot represent the entire tumor.


Liquid Biopsy is an emerging method developed to overcome these limitations of tissue biopsy.

Liquid Biopsy is a technology that can detect various genetic changes in cancer cells using the circulating tumor DNA (ctDNA) or circulating tumor cell (CTC), exosome, microRNA, tumor educated platelets. With the right sensitivity and specificity, these can be used for diagnosis, treatment decisions and monitoring of cancers. Among them, the first to be applied clinically was liquid biopsy using ctDNA from the peripheral blood.


Terms to Understand: Cell Free DNA (cfDNA) &

Circulating Tumor DNA (ctDNA)


cfDNA (cell free DNA) represents small pieces of DNA floating outside of the cells in various body fluids including blood. It exist in the human blood of healthy individuals at a concentration of 1-10ng/ml. cfDNA is known to be involved in various physiological and pathological processes including immunity, blood clotting, aging and cancer.


In cancer patients, a fraction of the cfDNA is tumor derived. These tumor derived DNA is called ctDNA and they carry the same genetic mutations present in the primary tumor cells. Generally, ctDNA is released upon death of the tumor cells and can be derived from both the circulating or living tumor cells.


What method is used to detect ctDNA?

Various Methods from Single variant analysis to full length genome analysis techniques are available for ctDNA analysis. The sensitivity and regions for detection may vary depending on the method chosen.

GCG-Oncomine Pan-cancer (LBx) Analysis Service among various techniques, use the NGS method to analyze ctDNA and report genetic variants.


We Recommend Liquid Biopsy to These Patients


  1. Stage 3-4 Advanced, Metastatic and/or Recurrent solid tumor patients.

  2. For cases in which tissue biopsy is difficult or additional tests cannot be conducted due to insufficient amount of tissue.

  3. Carcinoma of Unknown Primary (CUP) Patients

  4. For those who had negative result from previous test, but suspect variants to be detected and wish to take another test.


Download the required documents through the link below!

This test can be performed upon request from a medical doctor.


#Cancer Test#Non-Hereditary Solid tumor#Cancer#Genetic Test#Precision Oncology#SomaticCancer#NGSpanel#Liquid Biopsy#LBx#Oncomine Pan-cancer#Pan-cancer Cell-free Analysis

26 views

107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Korea

Email. info.gcgenome@gccorp.com Tel. +82 31-280-9900   Fax. +82 31-260-9087

©2020 by GC Genome.